( ent samples which showa correlation of...)Avalon Pharmaceuticals Announces Positive Interim Results For,AVN944 Phase I Trial,Health

ent samples which show a correlation of changes in gene expression in a dose dependent manner. Importantly, several of these markers display a durable, sustained stress response indicative of cancer cell death, particularly in cancer cells from AML patients. As dose levels increase the biomarkers reflect an even greater impact of AVN944 on the cancer cells. Direct markers of apoptosis are induced at these higher levels, including members of the Bcl2 gene family which play a critical role in programmed cell death. Additionally, the IMPDH enzyme is inhibited and GTP pools are also depleted for more sustained time periods in treated patients.

Potential Study Stratification Biomarker Data: Additionally we have identified a genetic signature, existing prior to drug exposure, which correlates strongly with disease stabilization in the first cycle of therapy. While still preliminary, based on a small patient sampling, this signature could be the foundation for future patient stratification strategies in phase II and III clinical trials.

Teleconference and Webcast: The company will host a conference call on Wednesday, June 20, 2007 at 8 a.m. Eastern Daylight Time to discuss the interim results of the AVN944 Phase I clinical trial. Interested investors, analysts, members of the media and the general public can listen to the call live over the Internet from the investor section of the company's Web site or by dialing the numbers listed below. A detailed PowerPoint presentation will accompany the webcast.

    Conference Call Details:


    Dial-In:           (800) 291-5365 (U.S.)

                       (617) 614-3922 (International)

                       Pass code:  74005634


    Webcast:           Please go to www.avalonrx.com, Investor Relations,

                       within 15 minutes prior to the call and select the

                       webcast link.  If listening by phone and viewing 
'"/>




Page: 1 2 3 4 5 6 
Related medicine technology :

1. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
2. Avalon Pharmaceuticals to Present at the American Association for
Cancer Research 2007 Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin
Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials &
Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH)